BLOG AND WHITEPAPERS
Recon takes an analytical look behind select developments in healthcare
Keep up with the Recon Strategy Insights
Get an email each time Recon takes an analytical look behind select developments in healthcare.
Search
- By Marc Herant
One more on the chin for Alzheimer’s
A report of a large phase 3 study of the highly potent oral BACE inhibitor verubecestat (Merck) with yet again a lack of therapeutic effect, despite a dramatic red…
- By Marc Herant
Are we nearing an asymptote with implantable cardiac pumps?
Severe heart failure is common, and spare hearts for transplant are rare, which has led to the development of implantable mechanical alterna…
- By Marc Herant
One way to think about disease[1] is as a loss of information[2] from the operating blueprint for human physiology. Broadly speaking, there are three main possible types of informational defects depe…
- By Tory Wolff
WMT is in talks with HUM about a relationship enhancement, possibly an acquisition. The two already know how to work together in alliances (narrow pharmacy network, marketing collaborations, points pr…
- By Tory Wolff
United’s OptumCare promises a lot of value for health plans. An integrated system supported by Optum technology should be able to deliver consistent, analytically sophisticated care. Its ambulatory-…
- By Marc Herant
GWAS, Regeneron and Geisinger, and liver disease
Genome wide association studies (GWAS) look at broad populations for gene variants associated with a particular phenotype. Often, like in Type II diabe…